Zynrelef vs Exparel: The Battle of Postoperative Pain Control After Robotic Sleeve Gastrectomy
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Zynrelef, Exparel.
- Who it may be relevant to
- Registry conditions: Post Operative Pain. Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The purpose of this study is to evaluate the use of an injectable combination of bupivacaine and meloxicam (Zynrelef) vs injectable liposomal bupivacaine (Exparel), two extended local anesthesia strategies currently approved by FDA and on the market for post-surgical pain control. The investigators plan on randomizing study participants to either Exparel or Zynrelef at the closure site of robotic sleeve gastrectomy and assessing their pain control postoperatively both in the hospital and at home. The investigators will measure the outcome of two drugs, Zynrelief, and Exparel on postoperative pain score -using the NRS pin score up to 72 hours after surgery. The total opioid use will be recorded in forms that will be used to measure pain score and total opioid use and will be collected to the Excel sheet. The cost of the drug will be calculated for internal use for Hospital purpose only.
Interventions
- Drug Zynrelef
Zynrelef will be injected at the 12mm port site - Drug Exparel
Exparel will be injected at the 12mm port site
Primary outcome measures
- postoperative pain score [Time frame: 72 hours]
Secondary outcome measures (2)
- Total postoperative opioid use [Time frame: 72 hours]
- Proportion of total rescue medication use [Time frame: 72 hours]
Eligibility criteria
Inclusion criteria
- Age range: 18-65 years old
- Scheduled or being scheduled to undergo robotic sleeve gastrectomy by Dr. Goyal.
- Is able to provide written informed consent.
- Is able to adhere to the study visit schedule and complete all study assessments.
Exclusion criteria
- Positive urine drug screen prior to surgery
- History of substance abuse in the past year-by self report
- Patient with ongoing daily narcotic use at the time of surgery-by self report
- Inability to understand informed consent or read English/Spanish
- Pregnant or lactating patients
- Prisoners
- Patients with renal or hepatic failure
- Bupivacaine use within 96 hours of operation
- Patient intolerant of opiates, nonsteroidal anti-inflammatory drug s, acetaminophen, or Zynrelef and Exparel. Subjects in all cohorts must not have any contraindications to any of the protocol-specified drugs
- Patient with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
United States · 1 center
- Texas Tech University Health Sciences Center — Lubbock
Identifiers
NCT: NCT06349772 · FY2024-203